How to appeal a UnitedHealthcare melanoma & melanoma-immunotherapy denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

UnitedHealthcare-specific note: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.

What UnitedHealthcare's policy requires for melanoma & melanoma-immunotherapy

Cited policy: OptumRx Keytruda (Pembrolizumab) for Melanoma PA

FDA-labeled indication: unresectable/metastatic melanoma OR adjuvant Stage IIB/IIC/III post-resection. Age ≥12 yr. ECOG 0-2 typically. Document AJCC 8th ed stage, primary site, BRAF status (informational, not required). Reauth q6mo with response assessment (RECIST or clinical) for metastatic; complete 1 yr adjuvant.

How UnitedHealthcare denies melanoma & melanoma-immunotherapy — and how to counter it

Where UnitedHealthcare pushes back: 1) PD-L1 negative — not appropriate; 2) BRAF-mutant should try BRAF/MEK first; 3) Stage IIB/IIC adjuvant 'low risk — observe'; 4) Neoadjuvant 'experimental' off-label.

Counter-arguments that hold up: PD-L1 is NOT label-restricted — KEYNOTE-006 + CheckMate-067 show benefit regardless. DREAMseq (Atkins JCO 2023) favors checkpoint-first in BRAF-mutant Stage IV (2-yr OS 72% vs 52%). KEYNOTE-716 (Luke Lancet 2022; Long JAMA 2024) supports Stage IIB/IIC adjuvant — Dec 2021 FDA. SWOG S1801 (Patel NEJM 2023) established neoadjuvant Keytruda standard of care for resectable Stage III.

What UnitedHealthcare typically denies for melanoma & melanoma-immunotherapy

Across UnitedHealthcare's commercial and Medicare books, denials cluster around a small number of patterns. For melanoma & melanoma-immunotherapy, expect:

• GLP-1 weight-loss exclusion
• Out-of-network reduction citing UCR
• Step therapy on biologics
• Prior auth denied for advanced imaging
• Quantity limits on specialty drugs

Treatments most often denied in this category

These are the melanoma & melanoma-immunotherapy treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Keytruda (pembrolizumab)
• Opdivo (nivolumab) mono
• Yervoy (ipilimumab)
• Opdivo + Yervoy combo
• Opdualag (nivo+rela)
• Tafinlar + Mekinist

How to submit the appeal to UnitedHealthcare

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document UnitedHealthcare cited in the denial.
3. File the appeal through UnitedHealthcare's portal (members: https://www.myuhc.com ; providers: https://www.uhcprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See UnitedHealthcare's prior-authorization criteria by drug: UnitedHealthcare PA criteria on ApprovalHelp.